Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
FlashNews:
Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.
ROA and and wander Unveil Their Second Collaborative Collection
Hyperliquid’s tokenized futures hit $1.2B as traders bet on oil, stocks
The ‘big brother’ helping Arteta’s Arsenal ‘over the line’
Kaine: Trump calling Iran war an ‘excursion’ is ‘deeply disrespectful’ to service members
The Best Things to Do in Rome Are Some of the Eternal City’s Oldest
Tomás Saraceno and Indigenous communities build art complex in Argentine salt flats
CBS News Justice correspondent Scott MacFarlane exits network
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
Home » Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.